Neuro Disorders Involving Epilepsy Include Distinct De Novo Variants
By LabMedica International staff writers Posted on 26 Jul 2018 |
Image: The NextSeq 550Dx next-generation sequencing system (Photo courtesy of Illumina).
Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.
Epilepsy is a frequent feature of neurodevelopmental disorders (NDDs), but little is known about genetic differences between NDDs with and without epilepsy. Anyone can develop epilepsy as epilepsy affects both males and females of all races, ethnic backgrounds and ages.
Scientists at the University of Leipzig Hospitals (Leipzig, Germany) and their international colleagues analyzed de novo variants (DNVs) in 6,753 parent–offspring trios ascertained to have different NDDs. In the subset of 1,942 individuals with NDDs with epilepsy, 529 of who had epilepsy syndromes termed epileptic encephalopathies (EE), while the remaining 1,413 of whom were classified as NDD with unspecified epilepsy.
The team used Illumina instruments to sequence protein-coding and searched for DNVs that corresponded to NDD with or without these types of epilepsy. The team noted that epilepsy was more common within groups of patients who had more severe forms of NDD. Likewise, DNVs in a set of 50 genes previously implicated in EE appeared more common in individuals with NDD who either had EE or unspecified epilepsy than in the epilepsy-free NDD cases.
Across the wider exomes, meanwhile, they saw an uptick in missense DNVs in the cases with both forms of epilepsy compared with those without, while highlighting 33 genes that were particularly prone to such alterations in the epilepsy-affected groups. That set included genes such KCNQ2, SCN2A, and SCN1A. When analyzing the full collection of NDD cases together, they flagged 101 DNV-prone genes, including 62 gene sets that had more missense DNVs in the NDD cases with epilepsy compared with the other NDDs.
In a series of follow-up analyses, the team took a closer look at the 33 genes with excess DNVs in the epilepsy-NDD cases, as well as the genes impacted by DNVs within the broader NDD cohorts. They identified 33 genes with a significant excess of DNVs, of which SNAP25 and GABRB2 had previously only limited evidence of disease association. Joint analysis of all individuals with NDDs also implicated CACNA1E as a novel disease-associated gene.
The authors concluded that that a little more than half of the DNVs in those genes would be picked up using two dozen available diagnostic sequencing panels for EE or other forms of epilepsy. Such data provided grounds for replacing genes with limited evidence with genes with higher evidence in the design of gene panels for NDDs with epilepsy. The study was published on June 25, 2018, in the journal Nature Genetics.
Related Links:
University of Leipzig Hospitals
Epilepsy is a frequent feature of neurodevelopmental disorders (NDDs), but little is known about genetic differences between NDDs with and without epilepsy. Anyone can develop epilepsy as epilepsy affects both males and females of all races, ethnic backgrounds and ages.
Scientists at the University of Leipzig Hospitals (Leipzig, Germany) and their international colleagues analyzed de novo variants (DNVs) in 6,753 parent–offspring trios ascertained to have different NDDs. In the subset of 1,942 individuals with NDDs with epilepsy, 529 of who had epilepsy syndromes termed epileptic encephalopathies (EE), while the remaining 1,413 of whom were classified as NDD with unspecified epilepsy.
The team used Illumina instruments to sequence protein-coding and searched for DNVs that corresponded to NDD with or without these types of epilepsy. The team noted that epilepsy was more common within groups of patients who had more severe forms of NDD. Likewise, DNVs in a set of 50 genes previously implicated in EE appeared more common in individuals with NDD who either had EE or unspecified epilepsy than in the epilepsy-free NDD cases.
Across the wider exomes, meanwhile, they saw an uptick in missense DNVs in the cases with both forms of epilepsy compared with those without, while highlighting 33 genes that were particularly prone to such alterations in the epilepsy-affected groups. That set included genes such KCNQ2, SCN2A, and SCN1A. When analyzing the full collection of NDD cases together, they flagged 101 DNV-prone genes, including 62 gene sets that had more missense DNVs in the NDD cases with epilepsy compared with the other NDDs.
In a series of follow-up analyses, the team took a closer look at the 33 genes with excess DNVs in the epilepsy-NDD cases, as well as the genes impacted by DNVs within the broader NDD cohorts. They identified 33 genes with a significant excess of DNVs, of which SNAP25 and GABRB2 had previously only limited evidence of disease association. Joint analysis of all individuals with NDDs also implicated CACNA1E as a novel disease-associated gene.
The authors concluded that that a little more than half of the DNVs in those genes would be picked up using two dozen available diagnostic sequencing panels for EE or other forms of epilepsy. Such data provided grounds for replacing genes with limited evidence with genes with higher evidence in the design of gene panels for NDDs with epilepsy. The study was published on June 25, 2018, in the journal Nature Genetics.
Related Links:
University of Leipzig Hospitals
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans